RECRUITING

A Phase Ib Study of Rezatapopt in Combination With Azacitidine or Azacitidine and Venetoclax in Patients With TP53Y220C Mutant Myeloid Malignancies (Acute Myeloid Leukemia or Myelodysplastic Syndrome)

Conditions

Myelodysplastic Syndrome Acute Myeloid Leukemia

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

A non-randomized phase Ib study of PC14586 (PMV therapeutics) in patients diagnosed with TP53Y220C-mutant myeloid malignancies, including AML and MDS.

Official Title

A Phase Ib Study of Rezatapopt in Combination With Azacitidine or Azacitidine and Venetoclax in Patients With TP53Y220C Mutant Myeloid Malignancies (Acute Myeloid Leukemia or Myelodysplastic Syndrome)

Quick Facts

Study Start:2025-01-30

Study Completion:2029-08-27

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:RECRUITING

Study ID

NCT06616636

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years

Sexes Eligible for Study:ALL

Accepts Healthy Volunteers:No

Standard Ages:ADULT, OLDER_ADULT

Inclusion Criteria	Exclusion Criteria
1. Patient is ≥ 18 years of age at the time of signing the informed consent form (ICF). 2. Patient is willing and able to adhere to the study visit schedule and other protocol requirements. 3. Patient has relapsed or primary refractory AML or MDS (cohort 1) 4. Patient has newly diagnosed AML or MDS (cohort 2) who is considered not eligible for intensive chemotherapy which must be defined as: Age 75 years or older, or Age 18 to 74 years with at least one of the following comorbidities: * 50%, or chronic stable angina). ii. Severe pulmonary disorder (eg, DLCO ≤65% or forced expiratory volume in 1 second \[FEV1\] * 65%). iii) Creatinine clearance ≥30 mL/min to \<45 mL/min. iii. Moderate hepatic impairment with total bilirubin \>1.5 to ≤3.0 × upper limit of normal (ULN) iv. ECOG performance status of \>2 5. Any other comorbidity that per the investigator renders a patient inappropriate for intensive chemotherapy. 6. Patients with MDS must be classified as MDS-IB1 or IB2 as per WHO 2022 criteria32 7. TP53Y220C mutation confirmed by CLIA-approved local testing with a variant allele frequency \>2%. 8. Patient has an Eastern Cooperative Oncology Group (ECOG) performance status of ≤2 9. Patient has adequate organ function defined as: 1. Serum aspartate aminotransferase/serum glutamic oxaloacetic transaminase (AST/SGOT) and alanine aminotransferase (ALT/SGPT) ≤ 3 x ULN, unless considered due to leukemic organ involvement. 2. Serum total bilirubin ≤ 1.5 x ULN. Higher levels are acceptable if these can be attributed to ineffective erythropoiesis, leukemia organ involvement or Gilbert\'s syndrome. 3. Serum creatinine \< 2 x ULN or creatinine clearance \> 40 mL/min based on validated glomerular filtration rate (GFR) estimation (Cockcroft-Gault, CKD-epi, or MDRD equations). 10. Females of childbearing potential may participate provided they have a negative serum or urine pregnancy test at screening and a negative serum OR urine pregnancy test within 72 hours of starting on treatment. They also must agree to either abstain from sexual intercourse or use two forms of a highly effective method of contraception while on study and up to 3 months after the last dose of the study drug. 11. Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) 14 days prior to study entry and for the duration of study participation. This includes all female patients between the onset of menses and 55 years unless the patient presents with an applicable exclusionary factor which may be one of the following: 12. Ability to understand and the willingness to sign a written informed consent document.	1. Patient has received prior chemotherapy, targeted therapy, immunotherapy, or treatment with an investigational anticancer agent within 14 days or 5 half-lives (if half-life is known), whichever is shorter, before receiving their first dose of study drug. 2. Patient has received radiotherapy within 14 days. 3. Patients with acute promyelocytic leukemia 4. Subject has immediate life-threatening, severe complications of leukemia such as uncontrolled bleeding, pneumonia with hypoxia or shock, and/or disseminated intravascular coagulation. 5. Patients with active, uncontrolled leukemia involvement of the CNS 6. Subject has known active viral infection with human immunodeficiency virus (HIV), or active infection with hepatitis B virus (HBV) or hepatitis C virus (HCV) 7. Subject is known to have dysphagia, short-gut syndrome, gastroparesis, or other conditions that limit the ingestion or gastrointestinal absorption of drugs administered orally. 8. Subject has active uncontrolled systemic fungal, bacterial, or viral infection (defined as ongoing signs/symptoms related to the infection without improvement despite appropriate antibiotics, antiviral therapy, and/or other treatment). 9. Patient has any unresolved toxicities from prior anti-cancer therapy greater than Grade 1 at the time of starting study treatment with the exception of alopecia and Grade 2 prior chemotherapy induced neuropathy. 10. Patient has had major surgery within 2 weeks prior to the planned start of study treatment. 11. Female subject who is pregnant or lactating. 12. History of allergic reactions attributed to compounds of similar chemical or biologic composition to azacitidine, venetoclax, rezetapopt or other agents used in study.

Inclusion Criteria

Exclusion Criteria

1. Patient is ≥ 18 years of age at the time of signing the informed consent form (ICF).
2. Patient is willing and able to adhere to the study visit schedule and other protocol requirements.
3. Patient has relapsed or primary refractory AML or MDS (cohort 1)
4. Patient has newly diagnosed AML or MDS (cohort 2) who is considered not eligible for intensive chemotherapy which must be defined as: Age 75 years or older, or Age 18 to 74 years with at least one of the following comorbidities:
* 50%, or chronic stable angina). ii. Severe pulmonary disorder (eg, DLCO ≤65% or forced expiratory volume in 1 second \[FEV1\]
* 65%). iii) Creatinine clearance ≥30 mL/min to \<45 mL/min. iii. Moderate hepatic impairment with total bilirubin \>1.5 to ≤3.0 × upper limit of normal (ULN) iv. ECOG performance status of \>2
5. Any other comorbidity that per the investigator renders a patient inappropriate for intensive chemotherapy.
6. Patients with MDS must be classified as MDS-IB1 or IB2 as per WHO 2022 criteria32
7. TP53Y220C mutation confirmed by CLIA-approved local testing with a variant allele frequency \>2%.
8. Patient has an Eastern Cooperative Oncology Group (ECOG) performance status of ≤2
9. Patient has adequate organ function defined as:
1. Serum aspartate aminotransferase/serum glutamic oxaloacetic transaminase (AST/SGOT) and alanine aminotransferase (ALT/SGPT) ≤ 3 x ULN, unless considered due to leukemic organ involvement.
2. Serum total bilirubin ≤ 1.5 x ULN. Higher levels are acceptable if these can be attributed to ineffective erythropoiesis, leukemia organ involvement or Gilbert\'s syndrome.
3. Serum creatinine \< 2 x ULN or creatinine clearance \> 40 mL/min based on validated glomerular filtration rate (GFR) estimation (Cockcroft-Gault, CKD-epi, or MDRD equations).
10. Females of childbearing potential may participate provided they have a negative serum or urine pregnancy test at screening and a negative serum OR urine pregnancy test within 72 hours of starting on treatment. They also must agree to either abstain from sexual intercourse or use two forms of a highly effective method of contraception while on study and up to 3 months after the last dose of the study drug.
11. Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) 14 days prior to study entry and for the duration of study participation. This includes all female patients between the onset of menses and 55 years unless the patient presents with an applicable exclusionary factor which may be one of the following:
12. Ability to understand and the willingness to sign a written informed consent document.

1. Patient has received prior chemotherapy, targeted therapy, immunotherapy, or treatment with an investigational anticancer agent within 14 days or 5 half-lives (if half-life is known), whichever is shorter, before receiving their first dose of study drug.
2. Patient has received radiotherapy within 14 days.
3. Patients with acute promyelocytic leukemia
4. Subject has immediate life-threatening, severe complications of leukemia such as uncontrolled bleeding, pneumonia with hypoxia or shock, and/or disseminated intravascular coagulation.
5. Patients with active, uncontrolled leukemia involvement of the CNS
6. Subject has known active viral infection with human immunodeficiency virus (HIV), or active infection with hepatitis B virus (HBV) or hepatitis C virus (HCV)
7. Subject is known to have dysphagia, short-gut syndrome, gastroparesis, or other conditions that limit the ingestion or gastrointestinal absorption of drugs administered orally.
8. Subject has active uncontrolled systemic fungal, bacterial, or viral infection (defined as ongoing signs/symptoms related to the infection without improvement despite appropriate antibiotics, antiviral therapy, and/or other treatment).
9. Patient has any unresolved toxicities from prior anti-cancer therapy greater than Grade 1 at the time of starting study treatment with the exception of alopecia and Grade 2 prior chemotherapy induced neuropathy.
10. Patient has had major surgery within 2 weeks prior to the planned start of study treatment.
11. Female subject who is pregnant or lactating.
12. History of allergic reactions attributed to compounds of similar chemical or biologic composition to azacitidine, venetoclax, rezetapopt or other agents used in study.

Contacts and Locations

Study Contact

Courtney DiNardo, MD

CONTACT

(713) 794-1141

cdinardo@mdanderson.org

Principal Investigator

Courtney DiNardo, MD

PRINCIPAL_INVESTIGATOR

The University of Texas MD Anderson Cancer Center

Study Locations (Sites)

The University of Texas MD Anderson Cancer Center

Houston, Texas, 77030

United States

Collaborators and Investigators

Sponsor: M.D. Anderson Cancer Center

Courtney DiNardo, MD, PRINCIPAL_INVESTIGATOR, The University of Texas MD Anderson Cancer Center

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2025-01-30

Study Completion Date2029-08-27

Study Record Updates

Study Start Date2025-01-30

Study Completion Date2029-08-27

Terms related to this study

Additional Relevant MeSH Terms

Myelodysplastic Syndrome
Acute Myeloid Leukemia